Table 5

Observed/expected number of deaths, SMR, and 95% CI for SBR related work area/job groups, 1944–98

		Colorectal cancer	Prostate cancer	Hodgkin’s disease	Multiple myeloma	All leukaemia	NHL
NHL, non-Hodgkin’s lymphoma.
Production, polymerisation	Obs/exp	22/24.6	23/19.7	0/1.4	1/3.8	18/8.8	11/8.0
	SMR	89	117	0	26	204	137
	(95% CI)	(56–135)	(74–175)	(0–260)	(1–146)	(121–322)	(69–246)
Production, coagulation	Obs/exp	14/11.8	9/9.5	0/0.7	0/2.0	10/4.3	4/4.0
	SMR	119	95	0	0	231	100
	(95% CI)	(65–200)	(43–180)	(0–569)	(0–183)	(111–425)	(27–256)
Production, finishing	Obs/exp	36/32.4	21/23.4	2/2.3	2/5.3	19/12.2	16/11.2
	SMR	111	90	88	38	156	143
	(95% CI)	(78–154)	(55–137)	(11–319)	(5–137)	(94–244)	(82–233)
Maintenance, shop	Obs/exp	16/11.3	9/9.4	0/0.7	1/1.7	4/4.3	4/3.8
	SMR	142	95	0	57	93	105
	(95% CI)	(81–231)	(44–181)	(0–530)	(1–320)	(25–238)	(29–268)
Maintenance, field	Obs/exp	41/33.5	21/27.3	1/1.9	3/5.0	10/11.9	11/10.6
	SMR	122	77	53	60	84	104
	(95% CI)	(88–166)	(48–118)	(1–296)	(12–175)	(40–155)	(52–186)
Labour, production	Obs/exp	12/10.6	11/11.7	0/0.7	4/2.1	4/3.3	4/2.5
	SMR	113	94	0	189	123	157
	(95% CI)	(58–198)	(47–168)	(0–547)	(52–483)	(34–315)	(43–403)
Labour, maintenance	Obs/exp	21/22.7	31/24.3	1/1.4	7/4.7	15/7.4	7/6.1
	SMR	93	128	74	150	203	115
	(95% CI)	(57–141)	(87–181)	(2–411)	(60–310)	(114–335)	(46–237)
Laboratories	Obs/exp	8/11.6	6/7.1	0/0.8	0/1.9	14/4.3	5/4.3
	SMR	69	84	0	0	326	117
	(95% CI)	(30–136)	(31–184)	(0–445)	(0–200)	(178–546)	(38–274)
Other operations	Obs/exp	20/24.3	15/19.5	2/1.4	4/3.9	6/8.7	4/7.9
	SMR	82	77	141	102	69	51
	(95% CI)	(50–127)	(43–127)	(17–508)	(28–261)	(25–150)	(14–131)